arrow_back Back to App

Excellence Centers for Drug Manufacturing: Faster, Better Medicines

This act aims to improve drug manufacturing in the U.S. by establishing specialized research centers. This could lead to faster, cheaper, and higher-quality drug production, potentially resulting in better availability and lower prices for citizens, especially during crises like drug shortages or pandemics.
Key points
National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing will be established to develop new, advanced drug production methods.
The goal is to enhance drug supply security, enable quicker responses to shortages and health crises, and improve pharmaceutical product quality.
These centers will collaborate with pharmaceutical companies and government agencies to implement innovations and train future professionals.
article Official text account_balance Process page
VOTING RESULTS
2021-10-19
87%
For 368
Against 56
Abstain 0
Full voting results open_in_new
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4369
Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6]
Process start date: 2021-07-06
Voting date: 2021-10-19
Meeting no: 1
Voting no: 318
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4369.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-06.

What are the main provisions?

Key points include:

  • National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing will be established to develop new, advanced drug production methods.
  • The goal is to enhance drug supply security, enable quicker responses to shortages and health crises, and improve pharmaceutical product quality.
  • These centers will collaborate with pharmaceutical companies and government agencies to implement innovations and train future professionals.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Pallone, Frank, Jr. [D-NJ-6].

What is the latest detailed status?

The latest detailed status is: The title of the measure was amended. Agreed to without objection.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Public Investments